NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
CRSP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. CRSP has a great financial health rating, but its profitability evaluates not so good. CRSP is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.8% | ||
ROE | -21.08% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 4.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 15.64 | ||
Quick Ratio | 15.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
36.29
-0.49 (-1.33%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 83.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.71 | ||
P/tB | 1.71 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.8% | ||
ROE | -21.08% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 7.23% | ||
Cap/Sales | 3.68% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 15.64 | ||
Quick Ratio | 15.64 | ||
Altman-Z | 4.87 |